chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 53-year-old male patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 26Sep2022 as dose 4 (booster), single (Lot number: GH9694) at the age of 52 years, in right arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown) and as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 16Mar2023, outcome "unknown" and all described as "Treatment of COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (16Mar2023) Positive, notes: Was barely positive on 16Mar; (17Mar2023) Positive, notes: Strong positive test on 18Mar. Therapeutic measures were taken as a result of drug ineffective, covid-19.  No follow-up attempts are possible. No further information is expected.
Full body hives a day after the 4th dose.  1st dose was taken 8/9/17 or 8/10/17 after getting the Yellow Fever Vaccine (injection).  I didn't have any reaction until after the 4th dose of the typhoid vaccine.  It started off with itching of my legs and head.  I took a Bendaryl that night and it helped, but the hives just moved to a different location.  I took another bendaryl the next morning and went to the doctors in the afternoon.  Hives were on my legs and stomach.   My doctor prescribed steroids and allergy medication to control it.  All of the hives went away slowly after 1.5 weeks.
Tested positive; Persistent cough; Body ache; Sweating; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (Tested positive), HYPERHIDROSIS (Sweating), COUGH (Persistent cough) and MYALGIA (Body ache) in a 41-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 048C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 25-Jul-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 25-Jul-2021, the patient experienced HYPERHIDROSIS (Sweating). On 26-Jul-2021, the patient experienced COVID-19 (Tested positive), COUGH (Persistent cough) and MYALGIA (Body ache). The patient was treated with PARACETAMOL (TYLENOL) in July 2021 for Adverse event, at a dose of 1 dosage form. In July 2021, HYPERHIDROSIS (Sweating) and MYALGIA (Body ache) had resolved. At the time of the report, COVID-19 (Tested positive) outcome was unknown and COUGH (Persistent cough) was resolving.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 26-Jul-2021, SARS-CoV-2 test: positive (Positive) Positive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications were provided.
Have had muscle pain in left arm since 3 days after shot.  Second shot on February 10 in right arm.  Have had muscle pain in right arm since three days after shot.  Muscle pain in both arms continues.  Have had elevated blood pressure coincident with the first shot.  Am being evaluated by my doctor for high blood pressure currently, although I suspect it is being caused by Covid vaccination.  Keeping BP record.
pt states several hours after she got the shot she developed 5 small itchy bumps that grew to dime size. she is unsure if it was due to the shot. I did not observe the bumps pt called by phone.
pt. c/o increasing left arm, nausea, dizziness with no resolve. VS 121/70, HR 71, O2 96%, P. placed in wheelchair and taken to triage for further evaluation. Pt. seen and evaluated by EMS and physician. Pt. lying on stretcher resting comfortably. Tolerating PO juice. Transported back to car to go home.
On 10/7/10 - during the evening, swelling, redness on Rt. thigh. Mother took pt. to ER. Given antibiotics. The next day 10/8/10, swelling and redness worse, returned to hospital, admitted 10/8/10. Discharged 10/11/10. Pt. discharged with oral antibiotics, and no other meds.
Per reporting nurse "Pt woke & rt side face swollen c red rash & if she ran her hand over her skin it felt dimply (or bumpy)"
On October 5th patient presented to the pharmacy stating that she has a warm, itchy, red area in the region of where she received her first Moderna shot. She states that she has been having this for several days.
DROP IN BLOOD PRESSURE; DIZZYNESS; CHILLS; HEADACHE; This spontaneous report received from a patient concerned a male of unspecified age. The patient's height, and weight were not reported. The patient's concurrent conditions included non alcohol user, and non smoker, and other pre-existing medical conditions included the patient had no known drug allergies and no any drug abuse / illicit drug use. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported and batch number: 1808982 expiry: UNKNOWN) dose was not reported, administered on 08-APR-2021 for prophylactic vaccination. No concomitant medications were reported. On 08-APR-2021, the subject experienced dizziness. On 08-APR-2021, the subject experienced chills. On 08-APR-2021, the subject experienced headache. On 09-APR-2021, the subject experienced drop in blood pressure. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient was recovering from chills, dizziness, headache, and drop in blood pressure. This report was non-serious.
Abrupt onset flushing, dizziness, metallic taste in mouth, feeling faint, nausea, tachycardia followed by splotches of erythema on left upper arm/shoulder and left face/neck which were still prevalent 1 hr later.
This case was reported by a consumer via call center representative and described the occurrence of suspected vaccination failure in a adult female patient who received SHINGRIX for prophylaxis. On an unknown date, the patient received the 2nd dose of SHINGRIX. On an unknown date, unknown after receiving SHINGRIX, the patient experienced vaccination failure (serious criteria GSK medically significant) and shingles. On an unknown date, the outcome of the vaccination failure and shingles were unknown. It was unknown if the reporter considered the vaccination failure and shingles to be related to SHINGRIX. Additional details were provided as follows: The age at vaccination was not reported. The patient got shingles after a second dose of SHINGRIX. The patient's demographics were declined. No other details were known. This case was considered as suspected vaccination failure cases as the vaccination schedule, time to event onset and laboratory results were unknown at the time of reporting. The reporter did not consent to follow-up.
5 days after second Moderna Covid vaccination, patient had sudden onset severe right leg swelling and pain, found to have extensive right lower extremity DVT and bilateral pulmonary embolism
numbness; tingling; This is a spontaneous report from a non-contactable Nurse, the patient. This male patient of unspecified age received BNT162B2 (Pfizer-BioNTech COVID-19 mRNA vaccine), via an unspecified route of administration on an unspecified date at single dose for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. On an unspecified date, the patient experienced numbness and tingling from the shoulder to the feet on the side the injection was given. The clinical outcome of the events numbness and tingling was unknown.     The lot number for the vaccine, BNT162B2, was not provided and will be requested during follow up.
Day of vaccination client complained of burning sensation & unable to lift anything heavy took ADVIL with little relief. Saw MD 10/20/12 who advised warm compresses and ice. Client still has pain & unable to lift arm above head.
On patient's body the evening of the influenza vaccination she developed a fever and on the following day she developed hives on her arms, legs and stomach.
Patient received Pfizer vaccine per EUA Emesis x1 with epigastric area "nausea" Vital signs and oximeter normal   Symptoms spontaneously resolved.   Routine post immunization instructions
Information has been received from a registered nurse concerning two patients who were vaccinated with a 0.5 mL dose of VARIVAX (Merck) (lot number 664717/0807Y). The nurse stated that the patients had a reported case of chickenpox. The patients did not seek medical attention. Follow up information received from the registered nurse via medical records indicated that the patient was a 12 months old female, with no illness at the time of vaccination and not known allergies, who on 03-MAR-2010 was vaccinated with a first dose of VARIVAX (Merck) (lot number 664717/0807Y), subcutaneously in her right thigh. Concomitant therapy included first doses of hepatitis A virus vaccine inactivated (manufacturer unknown) and MMR II (manufacturer unknown). The patient's past vaccination therapy included first doses of hepatitis B virus vaccine (unspecified) (manufacturer unknown), DTaP and Hib conj vaccine (unspecified carrier) on 04-MAY-2009. The patient received the second doses of hepatitis B virus vaccine (unspecified) (manufacturer unknown), DTaP and Hib conj vaccine (unspecified carrier) on 28-JUL-2009. A third dose of Hib conj vaccine (unspecified carrier) was given on 27-OCT-2009 along with the first doses of PREVNAR, ROTATEQ and PEDIARIX. A fourth dose of Hib conj vaccine (unspecified carrier) was given on 21-JUN-2010, on the same date the patient received the third dose of DTaP and the second dose of PREVNAR. On 01-SEP-2010 the patient had a visit to the physician's office where she was diagnosed with varicella zoster; (VZV AB IGG test performed on the same date was positive for VZV IgG antibody (3.65)), the patient had multiple vesicular erythematous reddish lesions, especially in her face, scalp and neck. The patient's physical examination was normal, the patient was alert. The patient's plan was treatment with acyclovir w5 ml, PO, QID v5d, CALADRYL lotion OTC topically and hydrocortisone cream. The reporter stated that the rash started in the left side of the face and was spreading; it started over the weekend. It was also reported that the patient had nasal drainage and congestion, was irritable and warm. At the 15-SEP-2010 visit the vesicular lesions were resolved, only reddish papules noted. It was reported that the patient was doing much better. During the cardiovascular examination the patient was noted to have a heart murmur (S1 S2 harsh). The rest of the physical examination was normal, the patient was alert. At the patient's 18 month visit on 23-SEP-2010, the varicella symptoms were resolving. For the heart murmur a follow up ped cardio was recommended. Flu vaccination was scheduled in one month. At the 26-OCT-2010 visit the varicella was completely resolved, the patient was doing fine, eating and drinking well, physical examination was normal. The patient had the second doses of influenza virus vaccine (unspecified) and hepatitis A virus vaccine inactivated (manufacturer unknown). The heart murmur outcome was unknown. Additional information has been requested.
Arm where vaccine was injected swelled to about the size of a golf ball starting at 0400AM and continued to worsen throught the day. Sore muscles and body aches occured throughout the body. Pain in the arm where vaccine was injected began to worsen throughout the day. Lymph node in the shoulder blade swelled on the side the vaccine was injected. All symptoms began to improve at around 11:00PM. By 9/6/2015 aches were minimal and pain improved. By 9/8/2015 swelling went down to normal. By 9/11/2015 lymph node returned back to normal.
This case was reported by a other health professional via call center representative and described the occurrence of rash in a female patient who received SHINGRIX for prophylaxis. Concurrent medical conditions included latex allergy. On an unknown date, the patient received the 1st dose of SHINGRIX. On an unknown date, less than a year after receiving SHINGRIX, the patient experienced rash. On an unknown date, the outcome of the rash was not recovered/not resolved. It was unknown if the reporter considered the rash to be related to SHINGRIX. Additional details were provided as follows: The age at vaccination was not reported. In 2018, the patient was given SHINGRIX 4 months ago and experienced ongoing rash on her trunk for the last 4 months. The healthcare professional (HCP) did not know that how long after the patient received SHINGRIX that she developed a rash on her trunk. The HCP also stated that the patient had a latex sensitivity so HCP confirmed there was no latex in the formulation of SHINGRIX.
accidentally given a half dose (0.25 ml) for 2nd primary series dose; This spontaneous case was reported by a pharmacist and describes the occurrence of ACCIDENTAL UNDERDOSE (accidentally given a half dose (0.25 ml) for 2nd primary series dose) in a male patient of an unknown age who received mRNA-1273 (Spikevax) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received second dose of mRNA-1273 (Spikevax) (Intramuscular) .25 milliliter. On an unknown date, the patient experienced ACCIDENTAL UNDERDOSE (accidentally given a half dose (0.25 ml) for 2nd primary series dose). At the time of the report, ACCIDENTAL UNDERDOSE (accidentally given a half dose (0.25 ml) for 2nd primary series dose) outcome was unknown.        For mRNA-1273 (Spikevax) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant medications details were not reported. Patient received a second Moderna primary series four weeks after the first primary series dose.  Treatment medication details were not reported.
Patient Complained of Pain in injection site, shooting up to neck 24 hrs after injection. Told to put ice on area and take Ibuprofen Followed up 48ho later and they said they felt better.
Swelling of right thigh with induration and erythema. Approximately 4 inches wide. Low grade fever x 1 day.
@ 24 hrs post-vaccine: egg-shaped area of rash on arm below shot site; @ 30 hrs post-vaccine: sudden onset of moderately severe muscle/joint pain and feeling feverish; @ 48 hrs post-vaccine: rash area has spread from upper arm almost to elbow and itches/burns/tingles slightly; @ 72 hrs post-vaccine: rash area has widened, and entire area sore to touch, itching, tingling but muscle/joint pain gone; @ 78 hrs post-vaccine, rash area remains same, muscle/joint pain has returned and slightly elevated temp recorded; @ 96 hrs post-vaccine: rash has retreated back to original goose-egg shaped area, and no further muscle/joint pain or fever has been experienced.
Information has been received from a physician concerning a female who on approximately 12-FEB-2007 was vaccinated intramuscularly with a dose of HPV. On approximately 12-FEB-2007 the patient fainted after the administration of HPV. It was reported that this patient may have fainted while on the way to the car and hit her head at an unspecified area. Medical attention was sought and the patient's mother was requesting a computed axial tomography because the patient was experiencing bad headaches. At the time of the report, the patient's outcome was unknown. Additional information has been requested.
Rash on left arm near vaccination site that formed 4 weeks later. looks similar to shingles type rash
Felt tired for about two days; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP).  A 91 year-old female patient received bnt162b2 (BNT162B2) (Lot number: EN6205) as dose number unknown, single for covid-19 immunisation. The patient's relevant medical history was not reported. The patient took concomitant medications. The following information was reported: FATIGUE (non-serious), outcome "recovered", described as "Felt tired for about two days". Additional Information: The patient felt tired for about two days, the 13th and 14th. Concomitant medication of the patient included Unspecified B12 Shot. The patient got a first vaccine shot on Friday and it was reported that she gets a B12 shot (Unspecified B12 shot) every now and then and she wanted to get her B12 shot and the reporter thought she got the first vaccine two days ago, so, maybe she should wait until she gets the second one. The reporter was querying if there was any information whether it was best for the patient to take that B12 shot.   No follow-up attempts are possible. No further information is expected.
Initial unsolicited misuse report received from a nurse on 19 March 2016. This case involves a patient who was vaccinated with a 0.1 ml dose of Fluzone QIV intradermally at the left forearm instead of TUBERCULIN PPD(M) 5 TU (Tubersol) on 18 March 2016. It was reported that on 18 March 2016 same day after vaccination patient had raised wheal at site on day of administration and the next day the wheal was raised, red, and warm to the touch. It was a case of wrong vaccine administered, Drug use via unapproved administration route and vaccine underdose. The patient was not recovered from the events. Follow-up information received from a nurse on 26-MAY-2016. This case involves a male patient (age not reported). On 18 March 2016, patient was administered with 0.1 ml of FLUZONE QIV (batch number UI440AB, expiry date 30-Jun-2016) via subcutaneous (SQ) route in left forearm. Patient's illness at the time of vaccination, pre-existing physician diagnosed allergies, birth defects, medical conditions were reported as unknown. Adverse event following prior vaccination in patient and in brother or sister was reported as unknown. Any other vaccination within four weeks prior to date of vaccination was reported as unknown. It was reported that the patient continued to have inflammation and tenderness over the site of the injection. Patient also experienced cellulitis of the left arm. On an unspecified date (2 days later), the patient had positive PPD test (10 mm) on right forearm On an unspecified date (2 days later), the patient received the corrective treatment for cellulitis with Keflex 500 mg, one per oral, daily for 10 days. It was reported that the on an unspecified date (after 4 days), the patient recovered from the event raised wheal at site (swelling) and for event cellulitis of left forearm the outcome was not reported. List of documents held by sender: none.
Unable to move left arm day after injection for 2 days.  Body aches so bad I couldn't move the 3rd day after shot lasted for 2 days after the body aches I had head to toe hives for 30 days, round the clock allergy meds to control the itching
Chills; headache; diarrhea; fever of 100.5; full body aches; right hip pain; This is a spontaneous report from a contactable consumer, the patient.  A 33-years-old non pregnant female patient received bnt162b2 (BNT162B2, formulation: solution for injection, lot number was not reported) via an unspecified route of administration, administered in arm left on 30Jul2021 at 17:30 as dose 1, single (age at vaccination 33 years) for covid-19 immunisation. Medical history included asthma, heart murmurs, prediabetes, high blood pressure, pcos and the patient was allergic to avocados. Concomitant medication(s) included hydrochlorothiazide, metformin and ascorbic acid, chromium, copper, folic acid, inositol, magnesium, manganese, nicotinamide, pantothenic acid, potassium, pyridoxine hydrochloride, retinol, riboflavin, selenium, vitamin b1 nos, vitamin b12 nos, vitamin e nos, zinc (MULTI VIT). On 31Jul2021 at 14:00 the patient experienced chills, headache, diarrhea, fever of 100.5, full body aches, right hip pain. The patient underwent lab tests which included body temperature 100.5 on 31Jul2021. The patient did not have covid prior to the vaccination. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient was not covid tested post vaccination. No therapeutic measures were taken as a result of the events. Prior to vaccination, the patient was not diagnosed with COVID-19. The outcome of all the events was recovered on an unknown date in 2021.  The lot number for the vaccine, [BNT162B2], was not provided and will be requested during follow up.
pt. experiencing lightheadedness/ dizziness, dry mouth & nausea.  pt. denies any other s/s.  Resolved with calming comfort measures.  pt able to drink water & eat a snack.
Started having joint pain, as in the flu at approx 7:30 that night, took two Tylenols and went to bed. Durning the night was weak and unstabble when i weant to the bathroon. at approx 6:30 the Sat. morning i went to the bathroom and when get back and set on the edge of the bed i started to slide of and was unable to stop. When i set on the floor, i started to lean to the right and i was to weak to hold myself upright. My wife came in and i was laying on the floor. she helped me into bed.  For the remainder of the 16th and until approx 7 sunday morning i was unable to get out of bed, it was like i was in a fog.  I was able to get out of bed sunday but remained weak. Monday the 18th i was back to my normal self.
A non-serious, spontaneous report of "gave it unknowingly to a pregnant women in her 3rd trimester" was received from a physician concerning a 35 year-old female. The patient's medical history included hypothyroidism, gestational diabetes, asthma and gastroesophageal reflux disease. Concomitant medications include levothyroxine since Feb-2008, glyburide since Nov-2008 and prenatal vitamins since May-2008. (Reference MEDI-0007555). The patient received FLUMIST for flu vaccination on 28-Oct-2008 during her 3rd trimester of pregnancy. The pregnancy was completed 2-Feb-2009 at full term via C-section. There were no complications with delivery and there were no adverse events, congenital anomalies or neonatal illness reported. Additional information was received on 27-Feb-2009 and incorporated into the narrative: pregnancy outcome.
1. After first dose had a rather sore arm that woke me up several times the first night. A few days later I started getting concerning but not severe headaches in the back of the head.  According to symptom reports I deemed it normal. 2. After second dose, no sore arm and NO SIDE EFFECTS  what soever, although my wife who got the vaccine the same time as I had the expected symptoms of feeling ill for about 12 hours on the next day.  3. My headaches continue even today even though I never had them before the vaccines.
Patient received the shot on 02-13-19. Two to three days later patient started to get hives and itching throughout the body. Patient came to the pharmacy and the pharmacist gave him some cooling gel. Patient still has hives and itching today 04-19-19. Patient went to another pharmacy today 041919 and the pharmacist there recommended BENADRYL and for him to call his doctor. Pharmacist from pharmacy called me here and explained the situation and gave me the patient's phone number. I called the patient and he had called his doctor and was waiting to hear back. I told the patient he did the right thing. Should be seen by his doctor and I would fill out a VAERS report. I would follow up with him on Saturday 042019.
10 days after my second Pfizer dose I developed headaches. On day 12, I found a rash on my forehead that became extremely painful. On day 14 I woke up with left-sided burning pain along the facial nerve and was diagnosed with shingles.
First off: pt had pain at injections site within minutes of receiving injection...  Later that evening, Patient had coughing and thought tongue and throat were swelling.  After visit to ER, physician there wasn't sure it was from flu shot but thought patient was having an allergic reaction of some type.  Was given a shot- steroids she thought- and Rx for antihistamines.  Patient also had "chest cold" that began the next day and continued for at least the next 6 days.  There was no latex used in administering the vaccine.